Company-wide revenue
Reported revenue in 2021 ¥340.45B Reported revenue in 2025 ¥364.4B
- growth amount
- +¥23.95B
- growth annualized
- +1.7%
- growth total
- +7.0%
Japanese company profile · 6523
PHC Holdings Corporation
In its FY2025 public filing, PHC Holdings Corporation reports Diabetes management, Healthcare solutions, Diagnostics and Life Sciences. The page shows business-level revenue and profit where the source disclosures support comparison.
Original Japanese company name: ＰＨＣホールディングス株式会社
English company name recorded in Japan's EDINET filer data. English company name source
Reported company-wide figures
What does this company do?
What does this company do?
PHC Holdings Corporation's largest reported business by revenue in FY2025 was Healthcare solutions.
The business with the highest reported segment profit in FY2025 was Diabetes management.
FY2025 · fiscal year ended March 2026 View original filing ↗ The source document may be in Japanese.
Business structure
How does it make money?
| Business | Revenue from external customers | Revenue share | Segment profit (loss) |
|---|---|---|---|
| Healthcare solutions | ¥128.39B ↗ | 35.2% | ¥6.23B ↗ |
| Diagnostics and Life Sciences | ¥128.32B ↗ | 35.2% | ¥3.89B ↗ |
| Diabetes management | ¥101.58B ↗ | 27.9% | ¥20.09B ↗ |
All values are in Japanese yen (JPY). No currency conversion is applied. FY2025 · fiscal year ended March 2026. Revenue and profit are shown only where the filing and data support a comparison.
Original Japanese label
- Diabetes management
- 糖尿病マネジメント
- Healthcare solutions
- ヘルスケアソリューション
- Diagnostics and Life Sciences
- 診断・ライフサイエンス
- Revenue from external customers
- 外部顧客売上
- Segment profit (loss)
- セグメント利益（損失）
Original Japanese label
- Diabetes management
- 糖尿病マネジメント
- Healthcare solutions
- ヘルスケアソリューション
- Diagnostics and Life Sciences
- 診断・ライフサイエンス
- Revenue from external customers
- 外部顧客売上
- Segment profit (loss)
- セグメント利益（損失）
Reported Revenue from external customers by business over time
Reported Revenue from external customers by business over time
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Diabetes management | ¥109.37B | ¥111.83B | ¥109.08B | ¥98.69B | ¥101.58B |
| Healthcare solutions | ¥136.29B | ¥133.55B | ¥133.41B | ¥128.31B | ¥128.39B |
| Diagnostics and Life Sciences | ¥92.22B | ¥108.77B | ¥109.05B | ¥130.92B | ¥128.32B |
All amounts are in Japanese yen (JPY). Each figure links to the original Japanese filing. Blank cells indicate no comparable figure was disclosed. Business figures may not add up to consolidated figures.
What is growing?
What is growing?
Business revenue growth
Diagnostics and Life Sciences
Reported revenue in 2021 ¥92.22B Reported revenue in 2025 ¥128.32B
- growth amount
- +¥36.1B
- growth annualized
- +8.6%
- growth total
- +39.1%
View original filing
Diagnostics and Life Sciences
Reported profit margin in 2022 -1.0%
Reported profit margin in 2025 +3.0%
- growth margin points
- +4.0
View original filing
This describes a reported period; it is not a forecast.
What has changed?
What has changed?
Not disclosed or not safely comparable in the available filings.
Source
Public filing
FY2025 · fiscal year ended March 2026
The source document may be in Japanese.
Filing ID: S100YHPK
View original filing ↗Ask about this company
Ask about this company
The source document may be in Japanese.